Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 8/20 | 0.66 |
| ▸ | GPR174 | Q9BXC1 | 4/20 | 0.66 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235835 | 1.00 | P2RY10 (0.66) | P2RY10GPR174GPR34 | |
| SCHEMBL28206519 | 0.93 | P2RY10 (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL236702 | 0.93 | P2RY10 (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL3409912 | 0.93 | P2RY10 (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL3406657 | 0.92 | P2RY10 (0.57) | P2RY10GPR174GPR34 | |
| SCHEMBL25351937 | 0.88 | SELP (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL234324 | 0.88 | SELP (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL235809 | 0.88 | SELP (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL22532037 | 0.88 | P2RY10 (0.78) | P2RY10GPR174GPR34 | |
| SCHEMBL20481087 | 0.88 | P2RY10 (0.78) | P2RY10GPR174GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408032-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2024-12-12 | — | — | US | claimed |
| EP-4398882-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2024-07-17 | — | — | EP | claimed |
| WO-2023036960-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2023-03-16 | — | — | WO | claimed |
| US-20240408032-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2024-12-12 | — | — | US | disclosed |
| EP-4398882-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2024-07-17 | — | — | EP | disclosed |
| CN-118265522-A | Lipid-based RNA formulations suitable for treatment | 生物技术欧洲股份公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20230302154-A1 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-09-28 | — | — | US | disclosed |
| WO-2023036960-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2023-03-16 | — | — | WO | disclosed |
| WO-2022040435-A1 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3357490-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND POLYPEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS | Children's Hospital Medical Center (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10039715-B2 | Liposomal formulation of nonglycosidic ceramides and uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2578237-A1 | Compositions and methods for enhancing contrast in imaging | Marval Biosciences, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012088414-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120020878-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120003159-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-05 | — | — | US | disclosed |
| US-20100311844-A1 | Spontaneously Forming Ellipsoidal Phospholipid Unilamellar Vesicles | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-09 | — | — | US | disclosed |
| US-7785568-B2 | Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography | MARVAL BIOSCIENCES, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20090142267-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2009-06-04 | — | — | US | disclosed |
| US-20080131369-A1 | Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography | MARVEL THERAPEUTICS (US) | 2008-06-05 | — | — | US | disclosed |
| US-20070212303-A1 | Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography | MARVAL PHARMA, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039715-B2 | Liposomal formulation of nonglycosidic ceramides and uses thereof | CERS2, CERT1, SGMS1 | P2RY10 1820/4885GPR174 2764/4885GPR34 1880/4885 |
| US-20240408032-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | PHOSPHO1, PLIN3, SARNP | P2RY10 4300/4885GPR174 3568/4885GPR34 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.